David Schlett joins Prime Therapeutics as Chief Financial Officer
Schlett is an experienced finance executive with more than 25 years of business, leadership experience. More about David's role at Prime
News from Prime
Mind the gap: Using a drug’s price-to-value calculation
Prime applies a price-to-value framework for high cost drugs. This helps drive a productive dialogue based on the value a drug can deliver to a a patient’s life.
Collaboration leverages scale and capabilities to drive greater value.
Small in number, but large in impact, “drug super spenders” need super attention
Just 0.03 percent of members have annual drug costs over $250,000. They account for 9 percent of total drug spend.
Prime in the news
Local organizations named Employers of Excellence
Sun ThisWeek
The New York Times
81 Minnesota Companies Land on Inc. 5000 List
Twin Cities Business
Prime Therapeutics, phData, Tattersall among Minnesota's Inc. 5000 companies
Minneapolis/St. Paul Business Journal
Prime Insights
Explore drug research, analyses and insights from Prime's pharmacy experts.
Get in touch
Connect with one of our media experts to learn more about the latest news and trends in the pharmacy benefit management industry.
Email the newsroom team
Sign-up for regular email updates
